Among these foci, some of the studies only evaluated the reliability of the two biomarkers for the screening and monitoring of preeclampsia, while others took into account sFlt-1/PlGF’s role in predicting intrauterine growth restriction as a complication of pregnant patients with preeclampsia. The gene discussed is PGF; the disease is fetal growth restriction.